Implant placement with or without simultaneous tooth extraction in patients taking oral bisphosphonates: Postoperative healing, early follow-up, and the incidence of complications in two private practices

Journal of Periodontology

Volumn 78, Issue 9, 2007, Pages 1664-1669

  Fugazzotto, Paul A ^a   Lightfoot, W Scott ^a   Jaffin, Robert ^a   Kumar, Ashkay ^a  

^a NONE   (United States)

Author keywords

Bisphosphonates; Dental implants; Osteonecrosis

Indexed keywords

EID: 34748853106     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2007.060514     Document Type: Article

References (25)

1. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in post-menopausal osteoporosis, N Engl J Med 1995;333:1437-1443.
2. Tonino RP, Meunier PJ, Emkey R, et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab 2000;85:3109-3115.
3. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. J Clin Endocrinol Metab 2000;85:4118-4124.
4. Marx RE. Pamidronate (Aredia) and zoledronic acid (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 2003;61: 1115-1117.
5. Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 2003;21:4253-4254.
6. Ruggiero SL, Mehrota B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 2004;62:527-534.
7. Bagan JV, Jimenez Y, Murillo J, et al. Jaw osteonecrosis associated with bisphosphonates: Multiple exposed areas and its relationship to teeth extractions. Study of 20 cases. Oral Oncol 2006;42:327-329.
8. Markiewicz MR, Margarone JE, Campbell JH, Aguirre A. Bisphosphonate- associated osteonecrosis of the jaws: A review of current knowledge. J Am Dent Assoc 2005;136:1669-1674.
9. Woo SB, Hellstein JW, Kalmar J. Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144: 753-761.
10. Bone Health and Osteoporosis. A Report of the Surgeon General. Rockville, MD: Department of Health and Human Services; 2004.
11. Sachs HC. One-year post exclusivity adverse event review. Alendronate. Center for Drug Evaulation and Research, Food and Drug Administration. Available at: http://www.fda.gov/ohrms/dockets/ac/04/slides/2004- 4067s1_07_Sachs%202%20Final.pdf.
12. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate- associated osteonecrosis of mandibular and maxillary bone: An emerging oral complication of supportive cancer therapy. Cancer 2005;104: 83-93.
13. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/ osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005; 63:1567-1575.
14. Edwards BJ, Hellstein JW, Jacobsen PL, Kaltman S, Mariotti A, Migliorati CA. Oral communication with C. Arsver, Merck and Co, Inc, March 2006, in Expert panel recommendations: Dental management of patients on oral bisphosphonate therapy, Report of the Council of Scientific Affairs; American Dental Association, June 2006.
15. Jeffcoat MK. Safety of oral bisphosphonates: Controlled studies on alveolar bone. Int J Oral Maxillofac Implants 2006;21:349-353.
16. Fugazzotto PA. Maintenance of soft tissue closure following guided bone regeneration: Technical considerations and report of 723 cases. J Periodontal 1999;70:1085-1097.
17. Albrektsson T, Zarb G, Worthington P, Eriksson RA. The long-term efficacy of currently used dental implant: A review and proposed criteria of success. Int J Oral Maxillofac Implants 1986;1:11-25.
18. Li J, Mashiba T, Burr DB. Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int 2001;69:281-286.
19. Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001;28:524-531.
20. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces biomechanical properties in dog rib. J Bone Miner Res 2000;15:613-620.
21. Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB. Does suppression of bone turnover impair mechanical properties by allowing microdamage accumulation? Bone 2000;27:13-20.
22. Akkus O, Polyakova-Akkus A, Adar F, Schaffler MB. Aging and microstructural compartments in human compact bone. J Bone Miner Res 2003;18:1012-1019.
23. Ciarelli TE, Fyhrie DP, Parfitt AM. Effects of vertebral bone fragility and bone formation rate on the mineralization levels of cancellous bone from white females. Bone 2003;32:311-315.
24. Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterones stimulated vascular regrowth in the ventral prostrate in castrated rats. Cancer Res 2002;62:6538-6544.
25. Shimura K, Shimazaki C, Taniguchi K, et al, Hyperbaric oxygen in addition to antibiotic therapy is effective for bisphosphonate induced osteonecrosis of the jaw in a patient with multiple myeloma. Int J Hematol 2006;84:343-345.